



11-27-07

IFW

Dkt. No. 29248/18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Erik Buntinx
Appl. No. : 10/725,965
Filed : December 2, 2003
For : A METHOD OF TREATING MENTAL DISORDERS
: USING OF D4 AND 5-HT2A ANTAGONISTS, INVERSE
: AGONISTS OR PARTIAL AGONISTS
Group Art : 1617
Examiner : UMAMAHESWARI RAMACHANDRAN
Customer No. : 1912

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

"Express Mail" mailing label No. EV 725837099 US
Date of Deposit: November 26, 2007

I hereby certify that this paper or fee is being
deposited with the United States Postal Service
"Express Mail" service under 37 CFR 1.10 on the date
indicated above and is addressed to the
Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450.

Name: Alan D. Miller

Signature:

Sir:

This Supplemental Information Disclosure Statement is being filed to
supplement the Information Disclosure Statements filed on August 24, 2007, April 10,
2007 and August 9, 2005 in connection with the above-identified application.

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant
would like to direct the Examiner's attention to the references that are listed on the
attached forms, PTO/SB/08A and PTO/SB/08B (2 pages). A copy of each non-U.S.
patent publication is also attached hereto.

Applicant: Erik Buntinx
Serial No.: 10/725,965
Filed: December 2, 2003
Page 2

Applicant would also like to advise the Examiner of the status of co-pending patent family members.

1. U.S. Patent Application No. 10/752,423. The claims have been subject to a restriction requirement. An Office Action on the merits of the application issued on October 2, 2007. A copy of the Office Action is attached hereto.

2. U.S. Patent Application No. 10/803,793. The claims have been subject to a restriction requirement. Office Actions on the merits of the application issued on May 3, 2007 and on October 19, 2007. A copy of each Office Action is attached hereto.

3. U.S. Patent Application No. 10/984,683. The claims have been subject to a restriction requirement. An Office Action on the merits of the application issued on August 10, 2007. A copy of the Office Action is attached hereto.

4. U.S. Patent Application No. 10/580,962. An examination report has not yet issued in connection with this application.


Applicant: Erik Buntinx
Serial No.: 10/725,965
Filed: December 2, 2003
Page 3

Applicant is submitting the subject Supplemental Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required in connection with this submission or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: November 26, 2007
New York, New York

By 
Alan D. Miller, Reg. No. 42,889